Search Results - "Poetschger, U."

Central nervous system relapse in high-risk stage 4 neuroblastoma: The HR-NBL1/SIOPEN trial experience by Berlanga, P., Pasqualini, C., Pötschger, U., Sangüesa, C., Castellani, M.R., Cañete, A., Luksch, R., Elliot, M., Schreier, G., Kropf, M., Morgenstern, D., Papadakis, V., Ash, S., Ruud, E., Brock, P., Wieczorek, A., Kogner, P., Trahair, T., Ambros, P., Boterberg, T., Castel, V., Valteau-Couanet, D., Ladenstein, R.

“…There is rising concern on the impact of new strategies, such as high-dose chemotherapy (HDC) and immunotherapy, on the pattern of relapse in high-risk…”
Get full text

Monitoring of adenovirus load in stool by real-time PCR permits early detection of impending invasive infection in patients after allogeneic stem cell transplantation by Lion, T, Kosulin, K, Landlinger, C, Rauch, M, Preuner, S, Jugovic, D, Pötschger, U, Lawitschka, A, Peters, C, Fritsch, G, Matthes-Martin, S

“…Invasive adenovirus (AdV) infections are associated with high morbidity and mortality in allogeneic stem cell transplant recipients. We observed that molecular…”
Get full text

Incidence and severity of crucial late effects after allogeneic HSCT for malignancy under the age of 3 years: TBI is what really matters by Bresters, D, Lawitschka, A, Cugno, C, Pötschger, U, Dalissier, A, Michel, G, Vettenranta, K, Sundin, M, Al-Seraihy, A, Faraci, M, Sedlacek, P, Versluys, A B, Jenkins, A, Lutz, P, Gibson, B, Leiper, A, Diaz, M A, Shaw, P J, Skinner, R, O'Brien, T A, Salooja, N, Bader, P, Peters, C

“…Younger children are considered to be more vulnerable to late effects (LE), which prompted us to study LE in patients after haematopoietic stem cell…”
Get full text

Early recipient chimerism testing in the T- and NK-cell lineages for risk assessment of graft rejection in pediatric patients undergoing allogeneic stem cell transplantation by Breuer, S, Preuner, S, Fritsch, G, Daxberger, H, Koenig, M, Poetschger, U, Lawitschka, A, Peters, C, Mann, G, Lion, T, Matthes-Martin, S

“…Timely diagnosis of impending graft rejection is crucial for effective therapeutic intervention after allogeneic hematopoietic stem cell transplantation (SCT)…”
Get full text

123I-mIBG scintigraphy in neuroblastoma: development of a SIOPEN semi-quantitative reporting ,method by an international panel by Lewington, V., Lambert, B., Poetschger, U., Sever, Z. Bar, Giammarile, F., McEwan, A. J. B., Castellani, Rita, Lynch, T., Shulkin, B., Drobics, M., Staudenherz, A., Ladenstein, R.

“…Purpose A robust method is required to standardise objective reporting of diagnostic 123 I-mIBG images in neuroblastoma. Prerequisites for an appropriate…”
Get full text

28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures by Ladenstein, R, Pötschger, U, Hartman, O, Pearson, A D J, Klingebiel, T, Castel, V, Yaniv, I, Demirer, T, Dini, G

“…Between 1978 and 2006, the European Group for Blood and Marrow Transplantation registered 4098 high-dose therapy (HDT) procedures followed by stem cell rescue…”
Get full text

Chromosome 14 copy number-dependent IGH gene rearrangement patterns in high hyperdiploid childhood B-cell precursor ALL: implications for leukemia biology and minimal residual disease analysis by Csinady, E, van der Velden, V H J, Joas, R, Fischer, S, de Vries, J F, Beverloo, H B, König, M, Pötschger, U, van Dongen, J J M, Mann, G, Haas, O A, Panzer-Grümayer, E R

“…Childhood B-cell precursor acute lymphoblastic leukemia (BCP ALL) is generally a clonal disease in which the number of IGH rearrangements per cell does not…”
Get full text

Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial by Ladenstein, Ruth, Prof, Pötschger, Ulrike, MSc, Pearson, Andrew D J, Prof, Brock, Penelope, MD, Luksch, Roberto, MD, Castel, Victoria, MD, Yaniv, Isaac, Prof, Papadakis, Vassilios, MD, Laureys, Geneviève, MD, Malis, Josef, MD, Balwierz, Walentyna, Prof, Ruud, Ellen, MD, Kogner, Per, Prof, Schroeder, Henrik, Prof, de Lacerda, Ana Forjaz, MD, Beck-Popovic, Maja, MD, Bician, Pavel, MD, Garami, Miklós, MD, Trahair, Toby, MD, Canete, Adela, MD, Ambros, Peter F, PhD, Holmes, Keith, MD, Gaze, Mark, MD, Schreier, Günter, PhD, Garaventa, Alberto, MD, Vassal, Gilles, Prof, Michon, Jean, MD, Valteau-Couanet, Dominique, MD

“…Summary Background High-dose chemotherapy with haemopoietic stem-cell rescue improves event-free survival in patients with high-risk neuroblastoma; however,…”
Get full text

Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis by Gadner, Helmut, Minkov, Milen, Grois, Nicole, Pötschger, Ulrike, Thiem, Elfriede, Aricò, Maurizio, Astigarraga, Itziar, Braier, Jorge, Donadieu, Jean, Henter, Jan-Inge, Janka-Schaub, Gritta, McClain, Kenneth L., Weitzman, Sheila, Windebank, Kevin, Ladisch, Stephan

“…Langerhans cell histiocytosis (LCH)-III tested risk-adjusted, intensified, longer treatment of multisystem LCH (MS-LCH), for which optimal therapy has been…”
Get full text

Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN Study by Holmes, Keith, Pötschger, Ulrike, Pearson, Andrew D J, Sarnacki, Sabine, Cecchetto, Giovanni, Gomez-Chacon, Javier, Squire, Roly, Freud, Enrique, Bysiek, Adam, Matthyssens, Lucas E, Metzelder, Martin, Monclair, Tom, Stenman, Jakob, Rygl, Michal, Rasmussen, Lars, Joseph, Jean-Marc, Irtan, Sabine, Avanzini, Stefano, Godzinski, Jan, Björnland, Kristin, Elliott, Martin, Luksch, Roberto, Castel, Victoria, Ash, Shifra, Balwierz, Walentyna, Laureys, Geneviève, Ruud, Ellen, Papadakis, Vassilios, Malis, Josef, Owens, Cormac, Schroeder, Henrik, Beck-Popovic, Maja, Trahair, Toby, Forjaz de Lacerda, Ana, Ambros, Peter F, Gaze, Mark N, McHugh, Kieran, Valteau-Couanet, Dominique, Ladenstein, Ruth Lydia

“…To evaluate the impact of surgeon-assessed extent of primary tumor resection on local progression and survival in patients in the International Society of…”
Get full text

Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1) by Bellini, Angela, Pötschger, Ulrike, Bernard, Virginie, Lapouble, Eve, Baulande, Sylvain, Ambros, Peter F, Auger, Nathalie, Beiske, Klaus, Bernkopf, Marie, Betts, David R, Bhalshankar, Jaydutt, Bown, Nick, de Preter, Katleen, Clément, Nathalie, Combaret, Valérie, Font de Mora, Jaime, George, Sally L, Jiménez, Irene, Jeison, Marta, Marques, Barbara, Martinsson, Tommy, Mazzocco, Katia, Morini, Martina, Mühlethaler-Mottet, Annick, Noguera, Rosa, Pierron, Gaelle, Rossing, Maria, Taschner-Mandl, Sabine, Van Roy, Nadine, Vicha, Ales, Chesler, Louis, Balwierz, Walentyna, Castel, Victoria, Elliott, Martin, Kogner, Per, Laureys, Geneviève, Luksch, Roberto, Malis, Josef, Popovic-Beck, Maja, Ash, Shifra, Delattre, Olivier, Valteau-Couanet, Dominique, Tweddle, Deborah A, Ladenstein, Ruth, Schleiermacher, Gudrun

“…In neuroblastoma (NB), the ALK receptor tyrosine kinase can be constitutively activated through activating point mutations or genomic amplification. We studied…”
Get full text

Persistence and reactivation of human adenoviruses in the gastrointestinal tract by Kosulin, K., Geiger, E., Vécsei, A., Huber, W.-D., Rauch, M., Brenner, E., Wrba, F., Hammer, K., Innerhofer, A., Pötschger, U., Lawitschka, A., Matthes-Leodolter, S., Fritsch, G., Lion, T.

“…Reactivation of persistent human adenoviruses (HAdVs) is associated with high morbidity and mortality in paediatric haematopoietic stem cell transplant (HSCT)…”
Get full text

Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification by Gadner, Helmut, Grois, Nicole, Pötschger, Ulrike, Minkov, Milen, Aricò, Maurizio, Braier, Jorge, Broadbent, Valerie, Donadieu, Jean, Henter, Jan-Inge, McCarter, Robert, Ladisch, Stephan

“…Multisystem Langerhans cell histiocytosis (MS-LCH) is associated with high mortality when patients have risk organ involvement (RO+) or are younger than 2…”
Get full text

Treosulfan-based conditioning regimens for allogeneic haematopoietic stem cell transplantation in children with non-malignant diseases by Slatter, M A, Boztug, H, Pötschger, U, Sykora, K-W, Lankester, A, Yaniv, I, Sedlacek, P, Glogova, E, Veys, P, Gennery, A R, Peters, C

“…An increasing number of children with non-malignant diseases can be cured by allogeneic haematopoietic stem cell transplantation (HSCT). Treosulfan ( L…”
Get full text

Risk stratification of high‐risk metastatic neuroblastoma: A report from the HR‐NBL‐1/SIOPEN study by Morgenstern, Daniel A., Pötschger, Ulrike, Moreno, Lucas, Papadakis, Vassilios, Owens, Cormac, Ash, Shifra, Pasqualini, Claudia, Luksch, Roberto, Garaventa, Alberto, Canete, Adela, Elliot, Martin, Wieczorek, Aleksandra, Laureys, Geneviève, Kogner, Per, Malis, Josef, Ruud, Ellen, Beck‐Popovic, Maja, Schleiermacher, Gudrun, Valteau‐Couanet, Dominique, Ladenstein, Ruth

“…Background Risk stratification is crucial to treatment decision‐making in neuroblastoma. This study aimed to explore factors present at diagnosis affecting…”
Get full text

High risk neuroblastoma (HR-NB) with MNA and age <18 months: Results from the HR-NBL1/SIOPEN trial by Ladenstein, Ruth Lydia, Poetschger, Ulrike, Valteau Couanet, Dominique, Ash, Shifra, Beck Popovic, Maja, Balwierz, Walentyna, Boterberg, Tom, Chan, Godfrey Chi-Fung, Elliott, Martin, Kogner, Per, Lode, Holger N., Laureys, Genevieve, Luksch, Roberto, Malis, Josef, Owens, Cormac, Papadakis, Vassilios, Sarnacki, Sabine, Taschner-Mandl, Sabine, Schleiermacher, Gudrun, Canete, Adela

“…10000 Background: The INES 99.4 trial (JCO 2009,27(7):1014-9) for MYCN amplified (MNA) infants using 6 courses of CBDCA-Vp16/CADO showed early progressions or…”
Get full text

Additive Prognostic Impact of Gastrointestinal Involvement in Severe Multisystem Langerhans Cell Histiocytosis by Minkov, Milen, Pötschger, Ulrike, Thacker, Nirav, Astigarraga, Itziar, Braier, Jorge, Donadieu, Jean, Henter, Jan-Inge, Lehrnbecher, Thomas, Rodriguez-Galindo, Carlos, Sieni, Elena, Nanduri, Vasanta, van den Bos, Cor, Abla, Oussama, Aricò, M., Gadner, H., Grois, N., Janka-Schaub, G., Ladisch, S., McClain, K., Weitzman, S., Windebank, K.

“…To evaluate the prognostic impact of gastrointestinal involvement on the survival of children with Langerhans cell histiocytosis (GI-LCH) registered with the…”
Get full text

Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN -Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group by Ambros, Inge M, Tonini, Gian-Paolo, Pötschger, Ulrike, Gross, Nicole, Mosseri, Véronique, Beiske, Klaus, Berbegall, Ana P, Bénard, Jean, Bown, Nick, Caron, Huib, Combaret, Valérie, Couturier, Jerome, Defferrari, Raffaella, Delattre, Olivier, Jeison, Marta, Kogner, Per, Lunec, John, Marques, Barbara, Martinsson, Tommy, Mazzocco, Katia, Noguera, Rosa, Schleiermacher, Gudrun, Valent, Alexander, Van Roy, Nadine, Villamon, Eva, Janousek, Dasa, Pribill, Ingrid, Glogova, Evgenia, Attiyeh, Edward F, Hogarty, Michael D, Monclair, Tom F, Holmes, Keith, Valteau-Couanet, Dominique, Castel, Victoria, Tweddle, Deborah A, Park, Julie R, Cohn, Sue, Ladenstein, Ruth, Beck-Popovic, Maja, De Bernardi, Bruno, Michon, Jean, Pearson, Andrew D J, Ambros, Peter F

“…For localized, resectable neuroblastoma without amplification, surgery only is recommended even if incomplete. However, it is not known whether the genomic…”
Get full text

Suppression of FOXO1 is responsible for a growth regulatory repressive transcriptional sub-signature of EWS-FLI1 in Ewing sarcoma by Niedan, S, Kauer, M, Aryee, D N T, Kofler, R, Schwentner, R, Meier, A, Pötschger, U, Kontny, U, Kovar, H

“…The Ewing sarcoma (ES) EWS-FLI1 chimeric oncoprotein is a prototypic aberrant ETS transcription factor with activating and repressive regulatory functions. We…”
Get full text

High dose chemotherapy and autologous hematopoietic cell transplantation for Wilms tumor: a study of the European Society for Blood and Marrow Transplantation by Spreafico, F., Dalissier, A., Pötschger, U., Locatelli, F., Michon, J. M., Peters, C., Bader, P., Bisogno, G., Yeomanson, D., Willasch, A., van den Heuvel Eibrink, M., Graf, N., Dallorso, S.

“…Survival for subgroups of patients with Wilms tumor (WT), such as those who suffer from relapse, is disappointing. Some patients’ treatment plans include…”
Get full text